Lercadip (Lercanidipine Hydrochloride)

Lercanidipine Hydrochloride is a dihydropyridine calcium channel blocker used in the management of hypertension.

• Hypertension: lowers systolic and diastolic blood pressure, improving cardiovascular risk profile.

• Lercanidipine Hydrochloride selectively blocks L‑type calcium channels on vascular smooth muscle cells. Inhibition of calcium influx prevents contraction, leading to vasodilation of peripheral arteries, decreased systemic vascular resistance, and consequently reduced arterial blood pressure. The drug’s high lipophilicity allows prolonged action and smooth muscle selectivity, minimizing direct cardiac effects.

Lercadip may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: sensation of warmth and redness, especially after the first dose.
• Peripheral edema: swelling of ankles or lower limbs due to fluid accumulation.
• Dizziness: light‑headed feeling, particularly when standing quickly.
• Tachycardia: increased heart rate without other cardiac pathology.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure leading to fainting.
• Angioedema: swelling of face, lips, tongue, or throat requiring urgent care.
• Hepatic enzyme elevation: abnormal liver function tests indicating possible liver stress.
• Myocardial infarction: rare occurrence of heart attack in susceptible individuals.
• Life‑threatening arrhythmias: irregular heart rhythms that may require medical intervention.

Before prescribing Lercadip, clinicians should consider several safety measures.

• Blood pressure monitoring: ensure adequate control and avoid excessive drops.
• Hepatic impairment: dose adjustment may be needed in patients with liver dysfunction.
• Elderly patients: start with the lowest effective dose and monitor for orthostatic effects.
• Concomitant antihypertensives: watch for additive hypotensive effects when combined with other agents.
• CYP3A4 inhibitors: avoid strong inhibitors that can increase lercanidipine plasma levels.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lercadip can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise lercanidipine concentrations and increase toxicity.
• Grapefruit juice: can markedly elevate plasma levels, leading to excessive hypotension.
• Other potent vasodilators (e.g., nitroglycerin): risk of severe blood pressure fall.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance antihypertensive effect and electrolyte disturbances.
• Beta‑blockers: combined use can cause additive heart rate reduction.
• Digoxin: monitor for signs of digoxin toxicity due to altered renal clearance.
• NSAIDs: may blunt antihypertensive response and affect renal function.